AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

It's hard to say anything negative about the Xencelabs Pen Display 24, because it does so much, so right. This is Xencelabs' first pen display drawing tablet, but you wouldn't know it to test it out.

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

“Ulcerative colitis can severely diminish a person’s quality of life and cause long-term health-related complications if it isn’t well managed,” said Professor Charlie Lees, Consultant ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for ...